Severity: Warning
Message: opendir(/var/lib/php/sessions): Failed to open directory: Permission denied
Filename: drivers/Session_files_driver.php
Line Number: 365
Backtrace:
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Background: We summarize the history of individuals with Sturge-Weber syndrome (SWS) to inform clinical trial design and identify variations in care.
Methods: We performed retrospective chart review of individuals with SWS from centers in New York City. We characterized data quality using a novel scoring system. For 13 clinical concepts, we evaluated if data were present and if they were of high quality.
Results: We included 26 individuals with SWS (58% female; median age at initial visit 7 years; absolute range 1 month to 56 years]). Twenty-two had nevus flammeus, 13 glaucoma, four homonymous hemianopia, and 15 hemiparesis. Nineteen of 21 had at least one confirmed seizure with a known first seizure date, all before 24 months. Most (18 of 26, 69%) epilepsy was controlled. A plurality (10 of 23, 43%) had either normal cognitive function or mild cognitive delays. Aspirin use varied by site (P = 0.02)-at four sites, use was 0% (zero of three), 0% (zero of four), 80% (four of five), and 64% (nine of 14). Data were present for more than 75% of cases for 11 of 13 clinical concepts (missing: age of diagnosis, age of glaucoma onset). There were gaps in level of detail for motor impairments, glaucoma severity, seizure history, cognition, and medication history.
Conclusions: Clinical charts have important gaps in the level of detail around core SWS clinical features, limiting value for some natural history studies. Any clinical trial in SWS designed to prevent epilepsy should begin in the first year of life. Variations in use of aspirin suggest de facto clinical equipoise and warrant a comparative effectiveness study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pediatrneurol.2022.08.009 | DOI Listing |
Ann Med Surg (Lond)
September 2025
Department of Pediatrics, Faculty of Medicine, University of Aleppo, Aleppo University Hospital (AUH), Aleppo, Syria.
Introduction And Importance: To document a rare case of Sturge-Weber syndrome (SWS) Type I with acute neurological symptoms.
Case Presentation: An 11-year-old boy, previously diagnosed with Sturge-Weber syndrome (SWS) Type I, presented to the emergency department with acute neurological symptoms that included vomiting, headaches, left-sided hemiparesis, and right-sided deviation of the labial commissure.
Clinical Discussion: Sturge-Weber syndrome (SWS) is a rare neurocutaneous disorder characterized by facial port-wine stains, leptomeningeal angiomas, and ocular involvement.
BMC Ophthalmol
August 2025
Department of Ophthalmology, Peking University First Hospital, Beijing, China.
Background: Sturge-Weber syndrome (SWS) is a rare congenital phacomatosis disorder. choroidal hemangioma (CH) is one of the most common ocular manifestations. The advancements in swept-source optical coherence tomography angiography (SS-OCTA) provide us a comprehensive view of the CH.
View Article and Find Full Text PDFCureus
July 2025
Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Sturge-Weber syndrome (SWS), also called encephalotrigeminal angiomatosis, is a congenital neurocutaneous disorder. It is characterized by facial and leptomeningeal angiomas as well as neurologic symptoms such as seizures and learning disabilities. We report a case of a 31-year-old male patient who presented with a history consistent with focal seizures.
View Article and Find Full Text PDFJ Neurodev Disord
August 2025
Department of Neurology and Developmental Medicine, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD, USA.
Sturge-Weber Syndrome (SWS) is a congenital neurovascular disorder caused by a somatic mosaic mutation in the R183Q GNAQ gene and characterized by capillary-venous malformations of the brain, skin, and eyes. Clinical manifestations include facial port-wine birthmark, glaucoma, seizures, headache or migraine, hemiparesis, stroke or stroke-like episodes, developmental delay, behavioral problems, and hormonal deficiencies. SWS requires careful monitoring, management, and early identification to improve outcome and prevent neurological deterioration.
View Article and Find Full Text PDFJ Biol Chem
August 2025
Department of Cell Biology and Physiology, Washington University in St Louis, St Louis, Missouri, USA. Electronic address:
Mutant constitutively active (CA) G protein α-subunits encoded by GNAQ or GNA11 (CA-GNAQ/11) drive uveal melanoma (UM), occur in uncommon subtypes of other cancers, and cause Sturge-Weber syndrome and other capillary malformations. CA-GNAQ/11 activates phospholipase Cβ, which cleaves phosphatidylinositol (4,5)-bisphosphate at high rate to produce diacylglycerol that drives oncogenesis and inositol (1,4,5)-trisphosphate (IP3) that releases Ca from intracellular stores and triggers store-operated Ca entry. For poorly understood reasons, high IP3 flux in UM cells does not elicit Ca overload and death.
View Article and Find Full Text PDF